Navigation Links
Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Date:5/2/2012

RARITAN, N.J., May 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE).

These submissions are supported by data from the global EINSTEIN program, which included two Phase 3 studies that evaluated the safety and efficacy of rivaroxaban in the treatment of patients with acute symptomatic DVT or PE and the prevention of recurrent, symptomatic VTE in these patients. The third Phase 3 study evaluated the safety and efficacy of rivaroxaban in the long-term prevention of recurrent symptomatic VTE. In total, these Phase 3 studies included more than 9,400 patients.

DVT is a condition in which blood clots form in one of the large, deep veins, usually in the legs. PE is a serious condition that most commonly occurs when part or all of a DVT dislodges and travels to the heart, where it can partially or completely block a branch of the pulmonary artery. When PE occurs with large clots, multiple clots, or when the patient already has pre-existing heart or lung disease, the event may be fatal.  VTE is the collective term for both DVT and PE. Each year an estimated 900,000 Americans experience an episode of VTE, resulting in an estimated 300,000 annual deaths.

About the EINSTEIN Program
The EINSTEIN program included three Phase 3 studies. The EINSTEIN-PE study was an open-label, randomized, non-inferiority trial. The trial compared oral rivaroxaban – 15 mg twice daily for three weeks, followed by 20 mg once daily – with the current standard of care of enoxaparin followed by a Vitamin K Antagonist (VKA) in patients with acute symptomatic PE with or without
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Janssen Research & Development, LLC Opens JANSSEN LABS at San Diego
2. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
3. Record Breaking $327 Million Verdict Upheld in Janssen Case and Request for New Trial Denied
4. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
5. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
6. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
7. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
8. Dr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research
9. Janssen Products, LP Modifies Prescribing Information for PROCRIT® (Epoetin alfa) in Chronic Kidney Disease
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
11. Record Breaking $327 Million Verdict Announced in Janssen Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 TWi ... final approval from the United States Food and ... Application (ANDA) for megestrol acetate 125mg/ml oral suspension, ... TWi is the first-to-file and under Hatch Waxman ... of marketing exclusivity.  TWi has completed the pre-launch ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a ... Terms & Agreements in Pharma, Biotech and ... The Co-development Terms and Agreements in ... understanding and unprecedented access to the co-development ... worlds leading life science companies. The ...
(Date:8/27/2014)... and MENLO PARK, Calif. , ... (OTCQB: DMPI), developer of advanced cancer therapeutics , ... 16th Annual Rodman & Renshaw Global Investment Conference, sponsored ... will take place Tuesday, September 9th at 2:55 p.m. ... the New York Palace Hotel in New ...
Breaking Medicine Technology:TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 2Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 3Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 4Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 5Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 6Co-development Terms & Agreements in Pharma, Biotech and Diagnostics 7DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
... Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or ... assembly, marketing and sale of medical devices and ... plans to release its financial results for the ... 31, 2011 on Monday, March 19, 2012, after the stock ...
... Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, ... Operating Officer of Aptuit LLC. Following the recent sale ... has been promoted from his previous position at Aptuit ... Needleman is responsible for all day-to-day operations of the ...
Cached Medicine Technology:Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer 2
(Date:8/28/2014)... 28, 2014 Bleeding gums are not to ... flossing, according to the prosthodontists at the Anacapa Dental Art ... serious medical conditions, Dr. Saj Jivraj and Dr. Mamaly Reshad ... are not properly cleaning your teeth all the way down ... bleed easily,” Dr. Jivraj said. , Despite their reputations for ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 In the ... and private practices struggle with: How can the overall ... new multi-year study of the healthcare industry tackles this ... correlation between employee job satisfaction and the quality of ... can be found in “ Organizational Factors related to ...
(Date:8/28/2014)... AMTC graduate, rising star and The Voice Season ... the Top 10 finalists for Pepsi’s Southern Original . He’s ... for his mentor and coach from The Voice and country music ... slot on Thursday, August 28th at 9:00 pm at Tootsie’s at ... will perform at the Gulf Coast Jam main stage on Sunday, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Top ... many web hosting companies and announces Bluehost, HostMonster ... recommended suppliers for the webmasters worldwide who want ... rates. , As the world’s most popular server-side ... and many other general-purpose programs. It is now ...
(Date:8/28/2014)... August 28, 2014 Alpine, NJ resident ... of his team, Zebras In Tiaras, to benefit the ... be held October 26, 2014 in Foley Square, New ... immunodeficiency community. Primary immunodeficiency diseases (PI) are a group ... which part of the body’s immune system is missing ...
Breaking Medicine News(10 mins):Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 2Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 3Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 4Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 5Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
... for Patient-Provider Decision MakingFurther Action Needed to Ensure ... Senate today improved on a comparative effectiveness research ... $1.1 billion dollar research effort on clinical effectiveness," ... of the National Alliance for Hispanic Health, the ...
... Ringling Bros.(R) Conservation and Breeding ProgramVIENNA, Va., Jan. 27 ... Elephant Conservation (R) proudly announces the ... twenty-second birth in what has proven to be the most ... importantly, this is the first calf in the Ringling ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) ... the market closes, it will report results for the ... February 24, 2009, at 9:00 a.m. Central Time, Healthcare ... results, quarterly activities,general operations of the Company and industry ...
... has completed a new study on uric acid and C8 and ... increased uric acid is associated with higher levels of C8 and ... can cause an increase in uric acid.The Science Panel team recently ... (also known as PFOA) and C8S (also known as PFOS) in ...
... St. Jude Children,s Research Hospital and the Children,s Oncology ... leukemia (ALL) scores of inherited genetic variations that clinicians ... more effective chemotherapy for this cancer. ... rates for ALL exceed 80 percent, patient responses vary ...
Cached Medicine News:Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:C8 Science Panel Completes Uric Acid Study 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: